Cytokine release syndrome caused by immune checkpoint inhibitor: a case report

doi:10.16352/j.issn.1001-6325.2022.11.1764

Abstract

Abstract: Objective To investigate the diagnosis and treatment of cytokine release syndrome (CRS) caused by immune checkpoint inhibitor(ICI). Methods A case of ICI pembrolizumab leading to CRS was analyzed in Department of Pulmonary and Critical Care Medicine of Peking Union Medical College Hospital. ResultsA 52-year-old woman with advanced adenosquamous lung cancer developed fever and hypotension after receiving pembrolizumab. Results of laboratory test showed an obviously increased serum ferritin, C response protein, interleukin-6 and abnormal liver function. Without positive infectious results, she was ultimately diagnosed as CRS. The patient was treated with steroids and tocilizumab with good clinical response. Conclusions CRS caused by ICIs develops rapidly and lead to severe results. It is important to consider CRS in patient who developed systemic inflammatory response syndrome after ICIs. Steroids combined tocilizumab is a potential choice of treatment.

Key words: immune checkpoint inhibitor, cytokine release syndrome, systemic inflammatory response syndrome, lung cancer

CLC Number:

R734.2

SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong. Cytokine release syndrome caused by immune checkpoint inhibitor: a case report[J]. Basic & Clinical Medicine, 2022, 42(11): 1764-1766.

References 7

[1]	Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature[J]. Front Immunol, 2022,13:807050. doi: 10.3389/fimmu.2022.807050.
[2]	Ceschi A, Noseda R, Palin K, et al. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database[J]. Front Pharmacol, 2020,11:557. doi: 10.3389/fphar.2020.00557.
[3]	Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Confer-ence Committee. American College of Chest Physicians/Society of Critical Care Medicine[J]. Chest, 1992,101:1644-1655.
[4]	Ciner AT, Hochster HS, August DA, et al. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review[J]. Immunotherapy, 2021,13:1071-1078.
[5]	Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy[J]. Pediatr blood cancer, 2017,64:e26642. doi: 10.1002/pbc.26642.
[6]	Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report[J]. J Immunother Cancer, 2021,9:e002855. doi: 10.1136/jitc-2021-002855.
[7]	Yomota M, Mirokuji K, Sakaguchi M, et al. Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-small-cell lung cancer[J]. Intern Med (Tokyo, Japan), 2021,60:3459-3462.

[1]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[2]	CAO Chenxin, TANG Hui, GENG Ruixuan, GUO Fuping, BAI Chunmei, WANG Yingyi, LI Taisheng. Correlation between circulating CD4⁺CD45RA⁺CD62L⁺ T cells and prognosis of metastatic non-small cell lung cancer treated with EGFR-TKI [J]. Basic & Clinical Medicine, 2024, 44(5): 658-664.
[3]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[4]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[5]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[6]	DING Fei, WANG Sa, HUANG Changxin. Serum CA211 level and NK cell number are associated with prognosis of patients with non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 180-184.
[7]	. Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC [J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
[8]	YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.
[9]	DAI Di, LIU Yuqin. Diagnostic difficulties and treatment progress of primary gastric lymphoma [J]. Basic & Clinical Medicine, 2023, 43(9): 1462-1466.
[10]	ZHANG Xiaowan, KANG Xia, YAO Xiaoying, XIE Fang, LI Ying. Silencing SF3B1 promotes apoptosis and inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(8): 1265-1270.
[11]	LI Zhen, DUAN Zhaojun, LUO Yunping. Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [J]. Basic & Clinical Medicine, 2023, 43(5): 777-784.
[12]	XUE Jianchao, WANG Yadong, LI Bowen, LIU Xinyu, LIANG Naixin, LI Shanqing. Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer [J]. Basic & Clinical Medicine, 2023, 43(3): 514-518.
[13]	ZHANG Jing, YANG Zigeng, WEI Hongmei, NING Haihong, XUE Xixi, JIN Ling, WU Bin. Knockdown of prohibitin 2 promotes apoptosis in non-small cell lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(10): 1522-1529.
[14]	GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.
[15]	ZHANG Jian, ZHANG Ji-jiong. LncRNA UNC5B-AS1 targeting miR-339-5p regulates the proliferation and apoptosis of human lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2022, 42(3): 454-460.